Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases.University of Rochester Center for Health and Technology (CHeT) Outcomes team develops and validates highly sensitive, disease-specific, regulatory-grade patient and caregiver reported outcome measures for therapeutic trials and drug labelling claims. Our Health Indexes span 40+ neurological, neuromuscular, and movement disorders and have been used worldwide in over 40 languages.
urmc.rochester.edu/chet/our-expertise/outcomes